Inactive Instrument

NurExone Biologic Inc. Toronto S.E.

ENER

CA29278Q1063

Biotechnology & Medical Research

EnerSpar Corp. Announces Resignation of Peter Bloch and Donal Carroll as Directors

August 10, 2019 at 01:30 am IST

EnerSpar Corp. announced that two former Directors, Peter Bloch and Donal Carroll, have resigned following the recent Annual and Special Meeting of shareholders.

Latest news about NurExone Biologic Inc.

NurExone Biologic Announces OTCQB Listing And DTC Eligibility	25/04	MT
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
NurExone Biologic Building a Research and Development Facility in Israel	09/03	MT
NurExone Biologic Inc. Establishes Research and Development Facility in Haifa, Israel	09/03	CI
NurExone Biologic Inc. Expands Intellectual Property Portfolio	21/02	CI
NurExone Launches Licensing Efforts For ExoTherapy Platform	15/02	MT
NurExone Biologic Inc. Launches Licensing Efforts for ExoTherapy Platform	15/02	CI
NurExone Biologic Provides Operations Update	20/23/20	MT
NurExone Biologic Posts Q1 Net Loss	24/23/24	MT
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, For Acute Spinal Cord Injuries Treatmenet	16/23/16	MT

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Sector

Biotechnology & Medical Research

Calendar

03/06/2024 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.23%	6.26TCr
IQVIA HOLDINGS INC.	-2.31%	4.12TCr
LONZA GROUP AG	+44.36%	4.03TCr
CELLTRION, INC.	-8.29%	2.79TCr
ICON PUBLIC LIMITED COMPANY	+11.97%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	1.91TCr
BIO-TECHNE CORPORATION	+7.54%	1.31TCr
MEDPACE HOLDINGS, INC.	+27.17%	1.21TCr
UNITED THERAPEUTICS CORPORATION	+25.72%	1.23TCr

Other Biotechnology & Medical Research

NurExone Biologic Inc. Toronto S.E.

Equities

ENER

CA29278Q1063

Biotechnology & Medical Research

EnerSpar Corp. Announces Resignation of Peter Bloch and Donal Carroll as Directors

Latest news about NurExone Biologic Inc.

Chart NurExone Biologic Inc.

Company Profile

Sector Other Biotechnology & Medical Research